Last reviewed · How we verify
Ph1b/2 Study of PF-04136309 in Combination With Gem/Nab-P in First-line Metastatic Pancreatic Patients (CCR2i)
The purpose of this Phase 1b/2 study is to evaluate the safety and tolerability of PF-04136309 in combination with nab-paclitaxel and gemcitabine, characterize the dose-limiting toxicities (DLTs) and overall safety profile of escalated doses of PF-04136309 and the associated schedule, determine the maximum tolerated dose (MTD), and to assess the enhancement of efficacy of PF-04136309 in combination with nab-paclitaxel and gemcitabine versus nab-paclitaxel + gemcitabine + placebo in terms of Progression Free Survival.
Details
| Lead sponsor | Pfizer |
|---|---|
| Phase | PHASE2 |
| Status | TERMINATED |
| Enrolment | 22 |
| Start date | Wed May 04 2016 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Tue Oct 10 2017 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Metastatic Pancreatic Ductal Adenocarcinoma
Interventions
- PF-04136309
- Nab-paclitaxel
- Gemcitabine
Countries
United States